Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2014; 6(8): 596-600
Published online Aug 27, 2014. doi: 10.4254/wjh.v6.i8.596
Published online Aug 27, 2014. doi: 10.4254/wjh.v6.i8.596
Pancreatic neuroendocrine tumor accompanied with multiple liver metastases
Tomohide Hori, Kyoichi Takaori, Shinji Uemoto, Department of Hepato-Pancreato-Biliary and Transplant Surgery, Kyoto University Hospital, Kyoto 606-8507, Japan
Author contributions: Hori T wrote the paper; Takaori K and Uemoto S supervised this paper.
Correspondence to: Tomohide Hori, MD, PhD, Department of Hepato-Pancreato-Biliary and Transplant Surgery, Kyoto University Hospital, 54 Shogoinkawara-cho, Sakyo-ku, Kyoto 606-8507, Japan. horit@kuhp.kyoto-u.ac.jp
Telephone: +81-75-7513651 Fax: +81-75-7513106
Received: April 18, 2014
Revised: June 25, 2014
Accepted: July 15, 2014
Published online: August 27, 2014
Revised: June 25, 2014
Accepted: July 15, 2014
Published online: August 27, 2014
Core Tip
Core tip: Pancreatic neuroendocrine tumor is rare. Current classifications predict its prognosis and postoperative recurrence. Curative resection is often difficult, because over 80% of patients have unresectable multiple liver metastases and extrahepatic metastasis. Aggressive or cytoreductive surgery for liver metastases is indicated to reduce hormone levels and improve symptoms and prognosis. Liver transplantation was originally conceived as an ideal therapy for unresectable liver metastases. However, there is no clear consensus on the role and timing of surgery for primary tumor and liver metastases.